...
首页> 外文期刊>Brachytherapy >American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III: Low-dose-rate and pulsed-dose-rate brachytherapy
【24h】

American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III: Low-dose-rate and pulsed-dose-rate brachytherapy

机译:美国近距离放射治疗协会对子宫​​颈局部晚期癌的共识性指南。第三部分:低剂量率和脉冲剂量率近距离放射疗法

获取原文
获取原文并翻译 | 示例

摘要

Purpose: To develop a guideline for quality practice of low-dose-rate (LDR) and pulsed-dose-rate (PDR) brachytherapy for locally advanced cervical cancer. Methods: Members of the American Brachytherapy Society (ABS) with expertise in cervical cancer brachytherapy formulated updated guidelines for LDR and PDR brachytherapy for locally advanced (International Federation of Gynecology and Obstetrics [FIGO] Stages IB2-IVA) cervical cancer based on literature review and clinical experience. Results: The ABS strongly recommends the use of brachytherapy as a component of the definitive treatment of locally advanced cervical carcinoma. Precise applicator placement is necessary to maximize the probability of achieving local control without major side effects. The ABS recommends a cumulative delivered dose of approximately 80-90. Gy for definitive treatment. Dosimetry must be performed after each insertion before treatment delivery. The dose delivered to point A should be reported for all intracavitary brachytherapy applications regardless of treatment planning technique. The ABS also recommends adoption of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology guidelines for contouring, image-based treatment planning and dose reporting. Interstitial brachytherapy may be considered for a small proportion of patients whose disease cannot be adequately encompassed by intracavitary application and should be performed by practitioners with special expertise in these procedures. Quality management measures must be performed, and follow-up information should also be obtained. Conclusions: Updated ABS guidelines are provided for LDR and PDR brachytherapy for locally advanced cervical cancer. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their clinical practices and to adopt dose-reporting policies that are critical for outcome analysis.
机译:目的:为低剂量率(LDR)和脉冲剂量率(PDR)近距离放射治疗局部晚期宫颈癌的质量实践制定指南。方法:基于文献回顾和临床经验。结果:ABS强烈建议将近距离放射治疗作为局部晚期宫颈癌的明确治疗手段之一。精确地放置喷头对于最大化实现局部控制而没有重大副作用的可能性是必要的。 ABS建议累计输送剂量约为80-90。 Gy进行最终治疗。每次插入后必须进行剂量测定,然后再进行治疗。无论采用何种治疗计划技术,都应报告所有腔内近距离放射治疗应用中到达A点的剂量。 ABS还建议采用EuropéendeCuriethérapie集团-欧洲放射治疗和肿瘤学学会的轮廓,基于图像的治疗计划和剂量报告的指南。间质近距离放射治疗可考虑用于一小部分不能通过腔内应用充分覆盖疾病的患者,并且应由对此过程具有专门知识的从业者进行。必须执行质量管理措施,并且还应获取后续信息。结论:为局部晚期宫颈癌的LDR和PDR近距离治疗提供了更新的ABS指南。鼓励从业者和合作组织使用这些指南制定其临床实践,并采用对结果分析至关重要的剂量报告政策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号